Amgen (AMGN) Shares are Up 0.35%

Amgen (AMGN) : Traders are bullish on Amgen (AMGN) as it has outperformed the S&P 500 by a wide margin of 4.4% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.38%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.35% in the last 1 week, and is up 4.8% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Amgen Inc. is up 16.28% in the last 3-month period. Year-to-Date the stock performance stands at 9.04%. The stock has recorded a 20-day Moving Average of 1.44% and the 50-Day Moving Average is 7.77%.


Amgen (NASDAQ:AMGN): The stock opened at $174.10 on Friday but the bulls could not build on the opening and the stock topped out at $174.96 for the day. The stock traded down to $172.26 during the day, due to lack of any buying support eventually closed down at $173.62 with a loss of -0.65% for the day. The stock had closed at $174.75 on the previous day. The total traded volume was 2,696,372 shares.

Also, Citigroup maintains its view on Amgen (NASDAQ:AMGN) according to the research report released by the firm to its investors. The shares have now been rated Neutral by the stock experts at the ratings house. Citigroup raises the price target from $165 per share to $175 per share on Amgen . The rating by the firm was issued on July 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Companys sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Companys products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.